Photo of Joaquim Bellmunt,  MD, PhD

Joaquim Bellmunt, MD, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute


joaquim_bellmunt@dfci.harvard.edu

Joaquim Bellmunt, MD, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Director Bladder Cancer Center, Medicine, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

My contributions as a clinician, researcher, and teacher have been well balanced.

I served as Section Chief, Solid Tumor Oncology (GU/GI) at Hospital del Mar in Barcelona for 7 years. Many patients with GU cancer especially bladder carcinoma were referred to me for consultation. I saw patients over 2 clinic days per week. The clinical practice included 7 full-time GU/GI oncologists, 1 laboratory-based GU oncologist, 1 dedicated GU research nurse, and 1 dedicated study coordinator.

In my research, I have focused on the development of new systemic treatments for cancers--in particular, bladder cancer and the search for prognostic factors and potential therapeutic targets. I developed the MCAVI (methotrexate, carboplatin and vinblastine) schedule for unfit patients (Cancer 1992) as the control arm for the EORTC 30986 study vs. GemCarbo (gemcitabine carboplatin) (JCO 2010). I reported the superiority of cisplatin vs. carboplatin in the randomized trial of MVAC (methotrexate, vinblastine, adriamycin and cisplatinum) vs. MCAVI (Cancer 1997). To improve the combination of CG (Cisplatin/Gemcitabine), we conducted an investigational phase I / II study with the 3-drug regimen of PCG (paclitaxel, cisplatin and gemcitabine) (JCO 2000). In 2001, we reported the feasibility study of the combination of GemCarbo (EurJCancer), which was used as the experimental arm of the EORTC 30986 study for a randomized trial of patients unfit for platinum (JCO 2012).

We confirmed the value of the MSKCC prognostic factors in the first-line treatment with chemotherapy in bladder cancer (TCG [paclitaxel, cisplatin, and gemcitabine] study, Cancer 2002). We also described, in the same group of patients, the role of ERCC1 expression as a predictor of CDDP (cisplatin) response in bladder cancer (Ann Oncol 2007).

Within the EORTC, I was the chairman of the Advanced Bladder Cancer Committee, and study Chair and co-chair for the 30987 and 30986 studies. To confirm the results of triple therapy with TCG, we designed the 30987 study, the largest study conducted in advanced bladder cancer comparing CG versus TCG (JCO 2012).

Looking for second-line options in patients failing platinum, we reported the phase III study of vinflunine versus placebo, which led to the approval of vinflunine in the European Union (JCO 2009). Based on this study, the role of prognostic factors in second-line treatment was described (JCO 2010).

In the area of new therapeutic targets, we reported the study of sunitinib in front-line therapy. In collaboration with Jonathan Rosenberg (DFCI), we analyzed the molecular profile of the Spanish bladder cancer patient series (ASCO 2011). Based on findings of PI3K mutations, we are studying in preclinical models the efficacy of PI3K and TOR1-2 inhibitor drugs in bladder cancer cell lines.

In RCC, the innovative contribution has been the clinical study exploring the role of the chemotherapy switch benefit described in the preclinical models by Dr. Hanrahan at M.D. Anderson Cancer Center in Houston.

My teaching duties have ranged from preceptor to UPF (Pompeu Fabra University) medical students, mentor to medical oncology residents and junior staff (Hospital del Mar), and presenter of national and international talks. Currently at DFCI I have the chance to teach and mentor several of our residents and oncology fellows in the clinical and translational field of urothelial cancer. This gives a great personal and professional satisfaction as well providing me with some very gratifying feedback. My passion for teaching is also fulfilled by the mentoring of two outstanding recently licensed doctors in their way to Urology and Oncology Residency; Dr. Jeffrey Leow and Dr.William Martin-Doyle. Both of them have finished a Master at the School of Public Health, Harvard and have worked closely with me to use state of the art and modern meta-analysis tools to pool together all the information on high grade T1 urothelial bladder and upper urinary tract tumors.

Since taking on my new DFCI role in March 2013, my contributions include:

Assumption of duties as Director of the Bladder Cancer Center

GU patient care, primarily bladder cancer patients

preliminary preparation of an application, with a letter of interest, for a grant in the area RFA-CA-12-018 (PQB3): Research Answers to NCIs Provocative Questions Group B (R21): Evaluating the functional consequences recurrence and progression-of epigenetic mutations derived from pT1G3 bladder tumor sequencing

submission of a proposal involving PROFILE, and using the OncoMap system and other clinical/research data for analysis in non-prostate GU tumors (urothelial transitional/non-transitional, penile, adrenal, and kidney), in collaboration with Toni Choueiri

involvement in the design of the new DFCI Bladder CRIS project

participation in the roll-out process for the four core GMAPs (GU-Management & Assessment Pathways), which include Prostate, Bladder, Renal, and Testicular cancer, with dedicated involvement in bladder cancer pathways

advising a group of Harvard students on the project Adjuvant Chemotherapy in Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials (Eur Urol, epub Aug. 28)

lecturing on bladder cancer for the Medical Oncology recertification exam

service on a monthly GU Oncology Tumor Board at BWH

Director of DFCI CRIS Project. Chairman of the Gelb Center

Director of DFCI GU Seminars

In addition, 22 Research Investigations and 18 Other Peer Reviewed Publications, several of them first- or senior-author contributions, have been published since then. Three new Clinical Guidelines are also in print.

I look forward to making future contributions to the Harvard community in terms of clinical expertise and innovation, research, administrative service, and teaching/training.

Publications

Powered by Harvard Catalyst
  • Farina MS, Lundgren KT, Bellmunt J. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives. Drugs 2017; 77:1077-1089. PubMed
  • Wankowicz SAM, Werner L, Orsola A, Novak J, Bowden M, Choueiri TK, de Torres I, Morote J, Freeman GJ, Signoretti S, Bellmunt J. Differential Expression Of Pd-L1 In High Grade T1 Vs Muscle Invasive Bladder Carcinoma And Its Prognostic Implications. J Urol 2017. PubMed
  • Fonteyne V, Ost P, Bellmunt J, Droz JP, Mongiat-Artus P, Inman B, Paillaud E, Saad F, Ploussard G. Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. Eur Urol 2017. PubMed
  • Necchi A, Raggi D, Giannatempo P, Sonpavde G, Galsky MD, Bellmunt J, Mariani L, Miceli R. From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. Clin Genitourin Cancer 2017. PubMed
  • Seisen T, Sun M, Lipsitz SR, Abdollah F, Leow JJ, Menon M, Preston MA, Harshman LC, Kibel AS, Nguyen PL, Bellmunt J, Choueiri TK, Trinh QD. Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol 2017. PubMed
  • García-Donas J, Font A, Pérez-Valderrama B, Virizuela JA, Climent MÁ, Hernando-Polo S, Arranz JÁ, Del Mar Llorente M, Lainez N, Villa-Guzmán JC, Mellado B, Del Alba AG, Castellano D, Gallardo E, Anido U, Del Muro XG, Domènech M, Puente J, Morales-Barrera R, Pérez-Gracia JL, Bellmunt J. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open Lancet Oncol. 2017. PubMed
  • De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res 2017; 5:312-318. PubMed
  • Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RC, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol 2017. PubMed
  • Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L, . Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol 2016; 71:281-289. PubMed
  • Teo MY, Bambury R, Zabor EC, Jordan EJ, Al-Ahmadie HA, Boyd M, Bouvier N, Mullane S, Cha EK, Roper N, Ostrovnaya I, Hyman DM, Bochner BH, Arcila ME, Solit DB, Berger MF, Bajorin DF, Bellmunt J, Iyer G, Rosenberg JE. DNA Damage Response and Repair Gene Alterations Are Associated With Improved Survival In Patients With Platinum-Treated Advanced Urothelial Carcinoma. Clin Cancer Res 2017. PubMed
  • Fossati N, Willemse PM, Van den Broeck T, van den Bergh RC, Yuan CY, Briers E, Bellmunt J, Bolla M, Cornford P, De Santis M, MacPepple E, Henry AM, Mason MD, Matveev VB, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Lam TB, Mottet N, Joniau S. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Eur Urol 2017. PubMed
  • Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQ, Juco J, Lunceford J, Saraf S, Perini RF, O'Donnell PH. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017. PubMed
  • Seisen T, Krasnow RE, Bellmunt J, Rouprêt M, Leow JJ, Lipsitz SR, Vetterlein MW, Preston MA, Hanna N, Kibel AS, Sun M, Choueiri TK, Trinh QD, Chang SL. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol 2017. PubMed
  • Bellmunt J, Bajorin DF. Pembrolizumab for Advanced Urothelial Carcinoma. N Engl J Med 2017; 376:2304. PubMed
  • Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF, . Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017; 376:1015-1026. PubMed
  • de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist 2017; 22:286-292. PubMed
  • Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Recine F, Alva A, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY, . Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer Med 2016. PubMed
  • Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF, . Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2016. PubMed
  • Seisen T, Jindal T, Karabon P, Sood A, Bellmunt J, Rouprêt M, Leow JJ, Vetterlein MW, Sun M, Alanee S, Choueiri TK, Trinh QD, Menon M, Abdollah F. Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. Eur Urol 2016. PubMed
  • Mullane SA, Bellmunt J. Cancer immunotherapy: new applications in urologic oncology. Curr Opin Urol 2016; 26:556-63. PubMed
  • Rose TL, Deal AM, Ladoire S, Créhange G, Galsky MD, Rosenberg JE, Bellmunt J, Wimalasingham A, Wong YN, Harshman LC, Chowdhury S, Niegisch G, Liontos M, Yu EY, Pal SK, Chen RC, Wang AZ, Nielsen ME, Smith AB, Milowsky MI, . Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer. Bladder Cancer 2016; 2:405-413. PubMed
  • Sonpavde G, Pond GR, Mullane S, Ramirez AA, Vogelzang NJ, Necchi A, Powles T, Bellmunt J. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. BJU Int 2016. PubMed
  • Ramos JD, Casey MF, Bamias A, De Giorgi U, Bellmunt J, Harshman LC, Ladoire S, Wong YN, Alva AS, Rosenberg JE, Galsky MD, Yu EY, . The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. Clin. Appl. Thromb. Hemost. 2016. PubMed
  • Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol 2016. PubMed
  • Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RC, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 2016. PubMed
  • de Morrée ES, Vogelzang NJ, Petrylak DP, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, Ochoa de Olza M, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, Li JS, de Wit R. Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post hoc Analysis of the Mainsail Study. JAMA Oncol 2016. PubMed
  • Vogelzang NJ, Fizazi K, Burke JM, De Wit R, Bellmunt J, Hutson TE, Crane E, Berry WR, Doner K, Hainsworth JD, Wiechno PJ, Liu K, Waldman MF, Gandhi A, Barton D, Jungnelius U, Fandi A, Sternberg CN, Petrylak DP. Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016. PubMed
  • Fay AP, de Velasco G, Ho TH, Van Allen EM, Murray B, Albiges L, Signoretti S, Hakimi AA, Stanton ML, Bellmunt J, McDermott DF, Atkins MB, Garraway LA, Kwiatkowski DJ, Choueiri TK. Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. J Natl Compr Canc Netw 2016; 14:820-4. PubMed
  • Bellmunt J, Zhou CW, Mullane SA, Werner L, Taplin ME, Fay AP, Choueiri TK, Orsola A, Takeda DY, Hahn WC, Kim J, Sonpavde G, Bowden M. Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. Br J Cancer 2016; 115:12-9. PubMed
  • Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E, Rosenberg JE. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol 2016. PubMed
  • Seisen T, Sun M, Leow JJ, Preston MA, Cole AP, Gelpi-Hammerschmidt F, Hanna N, Meyer CP, Kibel AS, Lipsitz SR, Nguyen PL, Bellmunt J, Choueiri TK, Trinh QD. Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol 2016. PubMed
  • Necchi A, Pond GR, Raggi D, Giannatempo P, Vogelzang NJ, Grivas P, Galsky MD, Bellmunt J, Sonpavde G. Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer 2016. PubMed
  • McKay RR, De Velasco G, Werner L, Bellmunt J, Harshman L, Sweeney C, Rosenberg JE, Hirsch M, Signoretti S, Van Allen EM, Walsh M, Vaishampayan U, McDermott DF, Choueiri TK. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer 2016. PubMed
  • Cejas P, Li L, O'Neill NK, Duarte M, Rao P, Bowden M, Zhou CW, Mendiola M, Burgos E, Feliu J, Moreno-Rubio J, Guadalajara H, Moreno V, García-Olmo D, Bellmunt J, Mullane S, Hirsch M, Sweeney CJ, Richardson A, Liu XS, Brown M, Shivdasani RA, Long HW. Chromatin immunoprecipitation from fixed clinical tissues reveals tumor-specific enhancer profiles. Nat Med 2016. PubMed
  • Sonpavde G, Bellmunt J. Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma. Nat Rev Urol 2016. PubMed
  • Gakis G, Schubert T, Alemozaffar M, Bellmunt J, Bochner BH, Boorjian SA, Daneshmand S, Huang WC, Kondo T, Konety BR, Laguna MP, Matin SF, Siefker-Radtke AO, Shariat SF, Stenzl A. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World J Urol 2016. PubMed
  • Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016. PubMed
  • Bellmunt J, Mottet N, De Santis M. Urothelial carcinoma management in elderly or unfit patients. EJC Suppl 2016; 14:1-20. PubMed
  • Nadal R, Bellmunt J. The evolving role of enzalutamide on the treatment of prostate cancer. Future Oncol 2016; 12:607-16. PubMed
  • Mullane SA, Bellmunt J. Re: John P. Sfakianos, Eugene K. Cha, Gopa Iyer, et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol 2015;68:970-7. Eur Urol 2016. PubMed
  • Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, De Velasco G, Tyburczy M, Hamieh L, Albiges L, Agarwal N, Ho TH, Song J, Pignon JC, Barrios PM, Michaelson MD, Van Allen EM, Krajewski KM, Porta C, Pal SK, Bellmunt J, McDermott DF, Heng DY, Gray KP, Signoretti S. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic Renal Cell Carcinoma. Clin Cancer Res 2016. PubMed
  • Mullane SA, Werner L, Rosenberg J, Signoretti S, Callea M, Choueiri TK, Freeman GJ, Bellmunt J. Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Sci Rep 2016; 6:27702. PubMed
  • Mullane SA, Werner L, Guancial EA, Lis RT, Stack EC, Loda M, Kantoff PW, Choueiri TK, Rosenberg J, Bellmunt J. Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. Clin Genitourin Cancer 2016. PubMed
  • Muralidhar V, Regan MM, Werner L, Nakabayashi M, Evan CP, Bellmunt J, Choueiri TK, Elfiky AA, Harshman LC, McKay RR, Pomerantz MM, Sweeney CJ, Taplin ME, Kantoff PW, Nguyen PL. Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer 2016. PubMed
  • van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, Bellmunt J, Bolla M, Briers E, Cornford P, Joniau S, Mason MD, Matveev V, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N. Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. Eur Urol 2016. PubMed
  • Harshman LC, Preston MA, Bellmunt J, Beard C. Diagnosis of Bladder Carcinoma: A Clinician's Perspective. 2015; 8:677-85. PubMed
  • de Velasco G, Krajewski KM, Albiges L, Awad MM, Bellmunt J, Hodi FS, Choueiri TK. Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunol Res 2015. PubMed
  • Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Eur Urol 2015. PubMed
  • Sonpavde G, Bellmunt J. Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business? Eur Urol 2015. PubMed
  • Giannatempo P, Pond GR, Sonpavde G, Raggi D, Naik G, Galsky MD, Bellmunt J, Necchi A. The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. Eur Urol 2015. PubMed
  • Fay AP, Bellmunt J. Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer? BJU Int 2015; 116:500-1. PubMed
  • Bellmunt J, Orsola A, Sonpavde G. Precision and predictive medicine in urothelial cancer: are we making progress? Eur Urol 2015. PubMed
  • Martin-Doyle W, Orsola A, Bellmunt J. Reply to K. Lu. J Clin Oncol 2015; 33:2716-7. PubMed
  • Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Choueiri TK, Necchi A, Di Lorenzo G, Bellmunt J. Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. J Urol 2015. PubMed
  • Sonpavde G, Pond GR, Choueiri TK, Mullane S, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Buonerba C, Rozzi A, Matsumoto K, Lee JL, Kitamura H, Kume H, Bellmunt J. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. Eur Urol 2015. PubMed
  • Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE, . Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 2015. PubMed
  • Murta-Nascimento C, Romero AI, Sala M, Lorente JA, Bellmunt J, Rodero NJ, Lloreta J, Hospital À, Burón A, Castells X, Macià F. The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona. Eur J Cancer Prev 2015; 24:335-9. PubMed
  • Sonpavde G, Pond GR, Mullane S, Qu AQ, Di Lorenzo G, Federico P, Necchi A, Rosenberg JE, Bellmunt J, Choueiri TK. Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. Clin Genitourin Cancer 2015. PubMed
  • Sonpavde G, Pond GR, Fougeray R, Bellmunt J. Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma. BJU Int 2015; 115:854-5. PubMed
  • Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, Selvarajah S, Barletta JA, Berman DM, de Muga S, Salido M, Gallardo E, Rojo F, Guancial EA, Bambury R, Mullane SA, Choueiri TK, Loda M, Stack E, Rosenberg J. HER2 as a target in invasive urothelial carcinoma. Cancer Med 2015. PubMed
  • Sonpavde G, Bellmunt J. Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change? Oncologist 2015; 20:461-3. PubMed
  • Montgomery B, Kheoh T, Molina A, Li J, Bellmunt J, Tran N, Loriot Y, Efstathiou E, Ryan CJ, Scher HI, de Bono JS. Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. Eur Urol 2015; 67:866-73. PubMed
  • Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S, González I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sánchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A, Montagut C. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clin Cancer Res 2015; 21:2157-66. PubMed
  • Fizazi K, Abrahamsson PA, Ahlgren G, Bellmunt J, Castellano D, Culine S, de Wit R, Gillessen S, Gschwend JE, Hamdy F, James N, McDermott R, Miller K, Wiegel T, Wirth M, Tombal B. Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol 2015; 67:904-12. PubMed
  • Leow JJ, Reese S, Trinh QD, Bellmunt J, Chung BI, Kibel AS, Chang SL. Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis. BJU Int 2015. PubMed
  • Sonpavde G, Jones BS, Bellmunt J, Choueiri TK, Sternberg CN. Future directions and targeted therapies in bladder cancer. Hematol Oncol Clin North Am 2015; 29:361-76, x. PubMed
  • Leow JJ, Orsola A, Chang SL, Bellmunt J. A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treat Rev 2015. PubMed
  • Leow JJ, Fay AP, Mullane SA, Bellmunt J. Perioperative therapy for muscle invasive bladder cancer. Hematol Oncol Clin North Am 2015; 29:301-18, ix. PubMed
  • Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Dreicer R, Chen YH, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Bellmunt J. Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. Clin Genitourin Cancer 2015; 13:185-92. PubMed
  • Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015. PubMed
  • Necchi A, Pond GR, Giannatempo P, Di Lorenzo G, Eigl BJ, Locke J, Pal SK, Agarwal N, Poole A, Vaishampayan UN, Niegisch G, Hussain SA, Singh P, Bellmunt J, Sonpavde G. Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. Clin Genitourin Cancer 2015; 13:178-84. PubMed
  • Bellmunt J. Bladder cancer. Hematol Oncol Clin North Am 2015; 29:xiii-xiv. PubMed
  • Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: J Clin Oncol 2015; 33:723-31. PubMed
  • Martin-Doyle W, Leow JJ, Orsola A, Chang SL, Bellmunt J. Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol 2015; 33:643-50. PubMed
  • Fay AP, Albiges L, Bellmunt J. Current role of cabozantinib in metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther 2015; 15:151-6. PubMed
  • Bellmunt J, Werner L, Leow JJ, Mullane SA, Fay AP, Riester M, Van Hummelen P, Taplin ME, Choueiri TK, Van Allen E, Rosenberg J. Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. PLoS ONE 2015; 10:e0124711. PubMed
  • Fay AP, Signoretti S, Callea M, Telό GH, McKay RR, Song J, Carvo I, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, Bellmunt J, Hodi FS, Freeman GJ, Elfiky A, Choueiri TK. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer 2015; 3:3. PubMed
  • Bambury RM, Bhatt AS, Riester M, Pedamallu CS, Duke F, Bellmunt J, Stack EC, Werner L, Park R, Iyer G, Loda M, Kantoff PW, Michor F, Meyerson M, Rosenberg JE. DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC Cancer 2015; 15:242. PubMed
  • Orsola A, Bellmunt J. The "artificial" docetaxel space: the evolving treatment paradigm of metastatic castration-resistant prostate cancer. Eur Urol 2014; 67:30-2. PubMed
  • Merseburger AS, Scher HI, Bellmunt J, Miller K, Mulders PF, Stenzl A, Sternberg CN, Fizazi K, Hirmand M, Franks B, Haas GP, de Bono J, de Wit R. Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int 2014; 115:41-9. PubMed
  • Plimack ER, Hoffman-Censits J, Rosenberg JE, Wong YN, Bellmunt J, Choueiri TK. Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. J Clin Oncol 2014; 32:4171-2. PubMed
  • Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515:558-62. PubMed
  • Bellmunt J, Suarez C, Gallardo E, Rodon J, Pons F, Bonfill T, Beltran M, Moya I, Galtes S, Albanell J, Carles J. Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma. Oncologist 2014; 19:917-8. PubMed
  • Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK, Bellmunt J. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 2014. PubMed
  • Riester M, Werner L, Bellmunt J, Selvarajah S, Guancial EA, Weir BA, Stack EC, Park RS, O'Brien R, Schutz FA, Choueiri TK, Signoretti S, Lloreta J, Marchionni L, Gallardo E, Rojo F, Garcia DI, Chekaluk Y, Kwiatkowski DJ, Bochner BH, Hahn WC, Ligon AH, Barletta JA, Loda M, Berman DM, Kantoff PW, Michor F, Rosenberg JE. Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res 2014; 20:1873-83. PubMed
  • Bellmunt J, Leow JJ. Hyponatremia associated with worse outcomes in metastatic renal cell cancer: a potential target for intervention? Eur Urol 2014; 65:731-2. PubMed
  • Bellmunt J, Selvarajah S, Rodig S, Salido M, de Muga S, Costa I, Bellosillo B, Werner L, Mullane S, Fay AP, O'Brien R, Barretina J, Minoche AE, Signoretti S, Montagut C, Himmelbauer H, Berman DM, Kantoff P, Choueiri TK, Rosenberg JE. Identification of ALK gene alterations in urothelial carcinoma. PLoS ONE 2014; 9:e103325. PubMed
  • Bellmunt J, Teh BT, Tortora G, Rosenberg JE. Molecular targets on the horizon for kidney and urothelial cancer. Nat Rev Clin Oncol 2013; 10:557-70. PubMed
  • Bellmunt J, Pons F, Orsola A. Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy. Curr Opin Urol 2013; 23:466-71. PubMed
  • Bellmunt J. Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patients. Eur Urol 2012; 63:198-200. PubMed
  • Bellmunt J, Petrylak DP. New therapeutic challenges in advanced bladder cancer. Semin Oncol 2012; 39:598-607. PubMed
  • Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bl Cancer 2016; 2:165-202. PubMed
Hide